EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia

Rachel Sharman iD, David Ray, Andrew Farmer, Poppy C E Green, Victoria Harris, Fredrik Karpe, Colin A Espie iD, Diana Mantripp, Thomas Marjot, Niall M McGowan, Jeremy W Tomlinson, Simon D Kyle

Journal of Sleep Research · 2026-10 · 35 (5)

DOI: 10.1111/jsr.70306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Sleep Research, online erschienen am 15.02.2026. Verfasst von Rachel Sharman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sir Jules Thorn Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Hyperglycemia, Cognitive Behavioral Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre, NIHR Oxford Health Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insomnia may play a causal role in type 2 diabetes (T2D). Addressing insomnia through cognitive behavioural therapy (CBTi) in people with non‐diabetic hyperglycaemia could potentially reduce the risk of progression to T2D. To inform a future randomised trial, we performed a feasibility study of digital CBT (dCBTi) in individuals at increased risk of T2D. Participants were identified from 10 primary care practices in the UK and given access to dCBTi. Outcomes were evaluated at baseline (Week‐0) and post‐treatment (Week‐11). Primary feasibility outcomes were ability to recruit and treatment engagement. We also quantified within‐group mean change (95% CI) in insomnia severity (Insomnia Severity Index), health‐related quality of life (EQ‐5D‐3L), depression (Center for Epidemiologic Studies Depression Scale), chronotype (reduced Morningness‐Eveningness Questionnaire), sleep (7‐day actigraphy and diary), continuous glucose monitoring (7‐days) and fasting blood metabolites (insulin, lipids, glucose and C‐reactive protein). The recruitment target was 20. Of 242 people completing screening, 36 were eligible and 24 were enrolled (age 65.5 ± 12.4 years, 70.8% female). Twenty‐three (96%) completed post‐intervention assessments. Treatment engagement was excellent (83.3% completed ≥ 4 sessions). The intervention was associated with a large reduction in insomnia severity [−4.7 (95% CI: −6.2 to −3.2), d = −1.4] and medium reduction in depressive symptoms [−2.7 (95% CI: −5.1 to −0.2), d = −0.5]. Sleep diary parameters tended to show greater improvement following intervention relative to actigraphy. There was evidence of a reduction in serum lactate, glycerol and triglycerides but no clear change in glucose or insulin. Results suggest a full trial is likely feasible and that people with NDH find the intervention acceptable and beneficial. Trial Registration: This trial was prospectively registered on the UKs clinical study registry, the ISRCTN (ISRCTN19682964, https://doi.org/10.1186/ISRCTN19682964 )

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersHyperglycemiaCognitive Behavioral TherapyHumansFemaleFeasibility StudiesMaleMiddle AgedAgedDiabetes Mellitus, Type 2Quality of LifeActigraphySleepDigital HealthContinuous Glucose MonitoringDepressionChronotype

Stichwörter der Autor:innen

digital cognitive behavioural therapyinsomniametabolic dysfunctionnon‐diabetic hyperglycaemiapre‐diabetes

Autor:innen und Institutionen

  • Sir Jules Thorn Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • NIHR Oxford Biomedical Research Centre, OUH Trust, Oxford, UK.

ORCID-Profile: Rachel Sharman, Colin A Espie

Förderung

  • NIHR Oxford Biomedical Research Centre
  • NIHR Oxford Health Biomedical Research Centre

Zitieren

APA

Sharman, R., Ray, D., Farmer, A., Green, P. C. E., Harris, V., Karpe, F., Espie, C. A., Mantripp, D., Marjot, T., McGowan, N. M., Tomlinson, J. W., & Kyle, S. D. (2026). Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia. Journal of Sleep Research, 35(5). https://doi.org/10.1111/jsr.70306

Vancouver

Sharman R, Ray D, Farmer A, Green PCE, Harris V, Karpe F, et al. Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia. Journal of Sleep Research. 2026;35(5). doi:10.1111/jsr.70306

BibTeX
@article{Sharman2026,
  author = {Sharman, Rachel and Ray, David and Farmer, Andrew and Green, Poppy C E and Harris, Victoria and Karpe, Fredrik and Espie, Colin A and Mantripp, Diana and Marjot, Thomas and McGowan, Niall M and Tomlinson, Jeremy W and Kyle, Simon D},
  title = {Sleep Improvement for Metabolic Health: A Feasibility Trial of a Digital Sleep Treatment in People With Insomnia and Non‐Diabetic Hyperglycaemia},
  journal = {Journal of Sleep Research},
  year = {2026},
  volume = {35},
  number = {5},
  doi = {10.1111/jsr.70306}
}
Kostenlos starten →